American Arbitration Association Panel Finds in Favor of Adocia in First Phase of Arbitration against Eli Lilly
|
|
Monday, 20 August 2018
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, announced today that the Arbitration Panel presiding over Adocia’s arbitration claims against Eli Lilly & Company (“Lilly”) has found in favor of Adocia on the first of the claims to be resolved, awarding Adocia USD 11.6 million, as compensa
|
|
|
You Might Like
Tweets about this
Other recent news in Press Releases
|